natgillin/translations-raw huggingface dataset:
The administration of Zirabev should be temporarily discontinued 
Dajanje zdravila Zirabev je treba začasno prekiniti:
4 ml solution in a vial (Type I glass) with a stopper (butyl rubber) containing 100 mg of bevacizumab. 
Štiri ml raztopine v viali (steklo tipa I) z zamaškom (butilna guma), ki vsebuje 100 mg bevacizumaba.
Zirabev will be administered in combination with chemotherapy treatment containing a fluoropyrimidine medicine. 
Zdravilo Zirabev boste prejeli v kombinaciji s kemoterapevtskim zdravljenjem, ki vsebuje zdravilo na osnovi fluoropirimidina.
In published literature reports, cases of non-mandibular osteonecrosis have been observed in patients under the age of 18 years treated with bevacizumab. 
V literaturi so pri bolnikih, mlajših od 18 let, ki so se zdravili z bevacizumabom, poročali o primerih osteonekroze izven spodnje čeljustnice.
The incidence of venous thromboembolic reactions in clinical trials was similar in patients receiving bevacizumab in combination with chemotherapy compared to those receiving the control chemotherapy alone. 
Pojavnost venskih trombemboličnih dogodkov v kliničnih preskušanjih je bila pri bolnikih, ki so prejemali bevacizumab v kombinaciji s kemoterapijo, in bolnikih v kontrolni skupini, ki so prejemali samo kemoterapijo, podobna.
Objective response rate Rate 
Objektivni odziv na zdravljenje delež
Of the 452 patients randomized at baseline, the majority of patients were white (80.0% in the Chemo alone group and 75.3% in the Chemo+bevacizumab group), had squamous cell carcinoma (67.1% in the Chemo alone group and 69.6% in the Chemo+bevacizumab group), had persistent/recurrent disease (83.6% in the Chemo alone group and 82.8% in the Chemo+bevacizumab group), had 1-2 metastatic sites (72.0% in the Chemo alone group and 76.2% in the Chemo+bevacizumab group), had lymph node involvement (50.2% in the Chemo alone group and 56.4% in the 
Od 452 bolnic, ki so jih randomizirali ob izhodišču, je bila večina belk (80,0 % v skupini, ki je prejemala samo kemoterapijo, in 75,3 % v skupini, ki je prejemala kemoterapijo + bevacizumab), večina je imela ploščatocelični karcinom (67,1 % v skupini, ki je prejemala samo kemoterapijo, in 69,6 % v skupini, ki je prejemala kemoterapijo + bevacizumab), dolgotrajno/ponavljajočo se bolezen (83,6 % v skupini, ki je prejemala samo kemoterapijo, in 82,8 % v skupini, ki je prejemala kemoterapijo + bevacizumab), metastaze na 1-2 mestih (72,0 % v skupini, ki je prejemala samo kemoterapijo, in 76,2 % v skupini, ki je prejemala kemoterapijo + bevacizumab), prizadete bezgavke (50,2 % v skupini, ki je prejemala samo kemoterapijo, in 56,4 % v skupini, ki je prejemala kemoterapijo + bevacizumab) ter interval brez platine, ki je trajal ≥ 6 mesecev (72,5 % v skupini, ki je prejemala samo kemoterapijo, in 64,4 % v skupini, ki je prejemala kemoterapijo + bevacizumab).
Fluoropyrimidine/irinotecan or fluoropyrimidine/oxaliplatin based chemotherapy 
kemoterapija na osnovi fluoropirimidina in irinotekana ali fluoropirimidina in oksaliplatina kemoterapija na osnovi fluoropirimidina in irinotekana ali fluoropirimidina in oksaliplatina + bevacizumab
These therapies in combination with Zirabev may increase the risk of severe side effects. 
Ta zdravila lahko v kombinaciji z zdravilom Zirabev povečajo tveganje za pojav hudih neželenih učinkov.
16 ml solution in a vial (Type I glass) with a stopper (butyl rubber) containing 400 mg of bevacizumab. 
Šestnajst ml raztopine v viali (steklo tipa I) z zamaškom (butilna guma), ki vsebuje 400 mg bevacizumaba.
In patients with NSCLC excluding predominant squamous histology, all Grade reactions were seen with a frequency of up to 9.3% when treated with bevacizumab plus chemotherapy compared with up to 5% in the patients treated with chemotherapy alone. 
Pri bolnikih z NSCLC, razen pri prevladujoči ploščatocelični histologiji, so neželene učinke vseh stopenj opazili s pogostnostjo največ 9,3 %, če so jih zdravili z bevacizumabom in kemoterapijo, pri bolnikih, ki so se zdravili samo s kemoterapijo, pa s pogostnostjo največ 5 %.
(12.0 vs 15.0 months; p = 0.6267) 
(12,0 meseca v primerjavi s 15,0 meseca; p = 0,6267)
Patients were randomised to platinum-based chemotherapy, cisplatin 80 mg/m2 intravenous infusion on day 1 and gemcitabine 1250 mg/m2 intravenous infusion on days 1 and 8 of every 3-week cycle for up to 6 cycles (CG) with placebo or CG with bevacizumab at a dose of 7.5 or 15 mg/kg intravenous infusion day 1 of every 3-week cycle. 
Bolnike so randomizirali na kemoterapijo na osnovi platine, cisplatin 80 mg/m 2 v obliki intravenske infuzije na 1. dan in gemcitabin 1.250 mg/m2 v obliki intravenske infuzije na 1. in 8. dan vsakega 3tedenskega cikla do največ 6 ciklov (CG) s placebom ali CG z bevacizumabom v odmerku 7,5 mg/kg ali 15 mg/kg v obliki i.v.
Intravitreal use Zirabev is not formulated for intravitreal use. 
Zdravilo Zirabev ni namenjeno intravitrealni uporabi.
● if you have or have had pain in the mouth, teeth and/or jaw, swelling or sores inside the mouth, numbness or a feeling of heaviness in the jaw, or loosening of a tooth tell your doctor and dentist immediately. 
● zdravniku in zobozdravniku nemudoma povejte, če imate ali ste imeli bolečine v ustih, zobeh in/ali čeljusti, otekline ali razjede v ustih, če se vam pojavi odrevenelost ali občutek teže v čeljusti ali če se vam je razmajal zob;
These reactions included infectious endophthalmitis, intraocular inflammation such as sterile endophthalmitis, uveitis and vitritis, retinal detachment, retinal pigment epithelial tear, intraocular pressure increased, intraocular haemorrhage such as vitreous haemorrhage or retinal haemorrhage and conjunctival haemorrhage. 
Med njimi so bili infekcijski endoftalmitis, intraokularno vnetje, kot so sterilni endoftalmitis, uveitis in vitritis, odstop mrežnice, raztrganje pigmentnega epitelija mrežnice, povišan očesni tlak, intraokularna krvavitev, kot so vitrealna ali retinalna krvavitev in konjunktivalna krvavitev.
The incidence of AEs, including Grade ≥3 AEs and SAEs, was similar between the two treatment arms. 
Pojavnost neželenih učinkov, vključno z neželenimi učinki stopnje ≥ 3 in resnimi neželenimi učinki, je bila pri obeh zdravljenih skupinah podobna.
In clinical trials across all indications the overall incidence of NCI-CTCAE v.3 Grade 3-5 bleeding reactions ranged from 0.4% to 6.9% in bevacizumab treated patients, compared with up to 4.5% of patients in the chemotherapy control group. 
V kliničnih preskušanjih pri vseh indikacijah je celokupna pojavnost krvavitev stopnje 3-5 po NCICTCAE v.3 znašala od 0,4 % do 6,9 % bolnikov, ki so se zdravili z bevacizumabom, v primerjavi z največ 4,5 % bolnikov v kontrolni skupini, ki se je zdravila s kemoterapijo.
This was a phase II randomised, double-blind, active-controlled clinical trial evaluating the efficacy and safety of bevacizumab in combination with 5-FU/FA as first-line treatment for metastatic colorectal cancer in patients who were not optimal candidates for first-line irinotecan treatment. 
To je bilo randomizirano, dvojno slepo, z učinkovino nadzorovano klinično preskušanje 2. faze, v katerem so ocenjevali učinkovitost in varnost bevacizumaba v kombinaciji s shemo 5-FU/FA kot prvo linijo zdravljenja bolnikov z metastatskim rakom debelega črevesa in danke, ki niso bili najprimernejši kandidati za prvo linijo zdravljenja z irinotekanom.
Tell your doctor straightaway if you are pregnant, become pregnant during treatment with this medicine, or plan to become pregnant in the near future. 
Če ste noseči, med zdravljenjem s tem zdravilom zanosite ali načrtujete zanositev v bližnji prihodnosti, o tem takoj obvestite zdravnika.
Some of the adverse reactions are reactions commonly seen with chemotherapy; however, bevacizumab may exacerbate these reactions when combined with chemotherapeutic agents. 
Nekateri izmed neželenih učinkov so učinki, ki jih pogosto opazimo pri kemoterapiji, vendar jih lahko bevacizumab poslabša, kadar ga uporabljamo v kombinaciji s kemoterapevtiki.
a 10 mg/kg every 2 weeks b Relative to control arm 
10 mg/kg vsaka 2 tedna glede na kontrolno skupino
Grade 3-5 reactions have been observed in up to 2.3% of patients treated with bevacizumab plus chemotherapy as compared with < 1% with chemotherapy alone (NCI-CTCAE v.3). 
Neželene učinke stopnje 3-5 so opazili pri največ 2,3 % bolnikov, ki so se zdravili z bevacizumabom in kemoterapijo, v primerjavi z < 1 % bolnikov, ki so prejemali samo kemoterapijo (NCI-CTCAE v.3).
A concentration dependent degradation profile of bevacizumab was observed when diluted with glucose solutions (5%). 
Pri redčenju bevacizumaba z raztopino glukoze (5 %), so opazili od koncentracije odvisen profil razpada.
Anti-tumour activity was not observed in two earlier studies among a total of 30 children aged > 3 years old with relapsed or progressive high-grade glioma when treated with bevacizumab and irinotecan (CPT-11). 
V 2 predhodnih študijah pri skupno 30 otrocih, starih > 3 leta, s ponavljajočim se ali napredovalim gliomom visoke stopnje, ki so se zdravili z bevacizumabom in irinotekanom (CPT-11), niso opazili protitumorske aktivnosti.
Zirabev is also used for the treatment of adult patients with persistent, recurrent or metastatic cervical cancer. 
Zdravilo Zirabev uporabljamo tudi za zdravljenje odraslih bolnic z dolgotrajnim, ponavljajočim se ali metastatskim rakom materničnega vratu.
It should not be administered as an intravenous push or bolus. 
Zdravila ne smemo dajati v obliki hitre intravenske infuzije ali bolusa.
In all clinical trials, bevacizumab was administered as an intravenous infusion. 
V vseh kliničnih preskušanjih so bevacizumab dajali v obliki i.v.
The primary endpoints of the trial were objective response rate and progression-free survival. 
Primarna opazovana dogodka v preskušanju sta bila objektivni odziv na zdravljenje in preživetje brez napredovanja bolezni.
E4599 was an open-label, randomised, active-controlled, multicentre clinical trial evaluating bevacizumab as first-line treatment of patients with locally advanced (stage IIIb with malignant pleural effusion), metastatic or recurrent NSCLC other than predominantly squamous cell histology. 
Preskušanje E4599 je bilo odprto, randomizirano, z učinkovino nadzorovano, multicentrično klinično preskušanje, v katerem so ocenjevali bevacizumab v prvi liniji zdravljenja bolnikov z lokalno napredovalim (stadij IIIb z malignim plevralnim izlivom), metastatskim ali ponavljajočim se NSCLC brez prevladujoče ploščatocelične histologije.
No trials have been conducted to investigate the pharmacokinetics of bevacizumab in renally impaired patients since the kidneys are not a major organ for bevacizumab metabolism or excretion. 
Preskušanj za proučevanje farmakokinetike bevacizumaba pri bolnikih z ledvično okvaro niso opravili, saj ledvice niso pomemben organ za presnovo ali izločanje bevacizumaba.
Peripheral s ensory neuropathy b, 
Bolezni živčevja periferna senzorična nevropatija b,
Testing for proteinuria is recommended prior to start of Zirabev therapy. 
Pred začetkom zdravljenja z zdravilom Zirabev je priporočljivo testiranje na proteinurijo.
Deutschland Pfizer Pharma PFE GmbH Tel: +49 (0)800 8535555 
Pfizer Pharma GmbH Tel: +49 (0)30 550055-51000
Zirabev is a concentrate for solution for infusion. 
Zdravilo Zirabev je koncentrat za raztopino za infundiranje.
Bevacizumab addition to multimodal standard of care treatment seemed to be tolerated in this paediatric population. 
Zdi se, da so bolniki v tej pediatrični populaciji bevacizumab kot dodatek multimodalnemu standardnemu zdravljenju dobro prenašali.
Trial BO17704 has demonstrated that both 7.5 mg/kg/q3wk and 15 mg/kg/q3wk bevacizumab doses increase progression free survival and response rate. 
V preskušanju BO17704 pa so dokazali, da oba odmerka, 7,5 mg/kg vsake 3 tedne in 15 mg/kg vsake 3 tedne, podaljšata preživetje brez napredovanja bolezni in povečata stopnjo odziva.
This was a Phase III randomised, controlled, open-label trial investigating bevacizumab 5.0 mg/kg every 2 weeks or 7.5 mg/kg every 3 weeks in combination with fluoropyrimidine-based chemotherapy versus fluoropyrimidine-based chemotherapy alone in patients with mCRC who have progressed on a first- line bevacizumab-containing regimen. 
To je bilo randomizirano, nadzorovano, odprto preskušanje 3. faze, v katerem so proučevali bevacizumab v odmerku 5,0 mg/kg vsaka 2 tedna ali 7,5 mg/kg vsake 3 tedne v kombinaciji s kemoterapijo na osnovi fluoropirimidina v primerjavi s samostojno kemoterapijo na osnovi fluoropirimidina pri bolnikih z mCRC, pri katerih je bolezen napredovala po prvi liniji zdravljenja po shemi, ki je vsebovala bevacizumab.
(16.2 vs. 12.0 months; p = 0.1342) 
(16,2 meseca v primerjavi z 12,0 meseca; p = 0,1342)
How to use Zirabev 
Kako uporabljati zdravilo Zirabev
Therapy should be withheld for elective surgery. 
Zdravljenje je treba prekiniti tudi v primeru načrtovanega kirurškega posega.
(16.2 vs 17.5 months; p = 0.3769) 
(16,2 v primerjavi s 17,5 meseca; p = 0,3769)
Overall survival - primary analysis Hazard ratio (95% CI) 
Celokupno preživetje - primarna analiza razmerje ogroženosti (95 % IZ)
Study E3200 used a 5 mg/kg/week equivalent dose of bevacizumab in bevacizumab-naïve patients, while study ML18147 used a 2.5 mg/kg/week equivalent dose of bevacizumab in bevacizumab-pretreated patients. 
V študiji E3200 so bevacizumab uporabljali v odmerku, enakovrednem 5 mg/kg/teden, pri bolnikih, ki ga pred tem še niso prejemali, medtem ko so v študiji ML18147 bevacizumab uporabljali v odmerku, enakovrednem 2,5 mg/kg/teden, pri bolnikih, ki so se z njim že zdravili.
• diarrhoea, nausea, vomiting and abdominal pain. 
• drisko, siljenje na bruhanje, bruhanje in bolečine v trebuhu.
An increased incidence of arterial thromboembolic reactions was observed in patients treated with bevacizumab across indications, including cerebrovascular accidents, myocardial infarction, transient ischaemic attacks, and other arterial thromboembolic reactions. 
Pri bolnikih, ki so se zdravili z bevacizumabom, so pri vseh indikacijah opazili povečano pojavnost arterijskih trombemboličnih dogodkov, vključno s cerebrovaskularnimi insulti, miokardnim infarktom, prehodnimi možganskimi ishemijami in drugimi arterijskimi trombembolični dogodki.
All of these findings were reversible upon discontinuation of bevacizumab and sunitinib malate (see Hypertension, Proteinuria, PRES in section 4.4). 
Po prekinitvi zdravljenja z bevacizumabom in sunitinibijevim malatom so bile vse ugotovitve reverzibilne (glejte ''Hipertenzija'', ''Proteinurija'' in ''Sindrom posteriorne reverzibilne encefalopatije'' v poglavju 4.4).
Congestive heart failure (CHF) (see section 4.8) 
Kongestivno srčno popuščanje (KSP) (glejte poglavje 4.8)
Bvb + IFNa 
bv b + IFN
These clinically significant adverse reactions were reported in clinical trials but the grade 3-5 reactions did not meet the threshold of at least a 2% difference compared to the control arm. Table 2 also includes clinically significant adverse reactions that were observed only in the postmarketing setting, 
O teh klinično pomembnih neželenih učinkih so poročali v kliničnih preskušanjih, vendar neželeni učinki stopnje 3-5 niso dosegli praga vsaj 2 % razlike v primerjavi s kontrolno skupino.
Effect of bevacizumab on the pharmacokinetics of other antineoplastic agents 
Vpliv bevacizumaba na farmakokinetiko drugih zdravil z delovanjem na novotvorbe
Zirabev is for intravenous use. 
Zdravilo Zirabev je namenjeno za intravensko uporabo.
Paclitaxel/ bevacizumab (n=368) 
paklitaksel in bevacizumab (n = 368)
Two of the eight cases did not have radiological confirmation via MRI. 
V kliničnih preskušanjih so poročali o 8 primerih PRES. Dveh od teh 8 primerov niso radiološko potrdili z magnetnoresonančnim slikanjem.
Cases of foetal abnormalities in women treated with bevacizumab alone or in combination with known embryotoxic chemotherapeutics have been observed (see section 4.6 ) 
Prirojene in dedne genetske okvare pri ženskah, ki so se zdravile z bevacizumabom samim ali v kombinaciji z znano embriotoksičnimi kemoterapevtiki, so opazili primere nenormalnosti ploda (glejte poglavje 4.6)
Number of patients Overall survival Median time (months) 95% CI 
Število bolnikov Celokupno preživetje mediani čas (meseci) 95 % IZ
● a blood clot in your arteries, 
● krvni strdek v arterijah,
Caution should be taken when treating these patients with Zirabev. 
Pri zdravljenju teh bolnikov z zdravilom Zirabev je zato potrebna previdnost.
• ML18147: Bevacizumab 5.0 mg/kg of body weight every 2 weeks or bevacizumab 7.5 mg/kg of body weight every 3 weeks in combination with fluoropyrimidine/irinotecan or fluoropyrimidine/oxaliplatin in patients with disease progression following first-line treatment with bevacizumab. 
ML18147: bevacizumab 5,0 mg/kg telesne mase vsaka 2 tedna ali bevacizumab 7,5 mg/kg telesne mase vsake 3 tedne v kombinaciji s fluoropirimidinom in irinotekanom ali fluoropirimidinom in oksaliplatinom pri bolnikih, pri katerih je bolezen napredovala po prvi liniji zdravljenja z bevacizumabom.
These results suggest that close clinical observation with appropriate cardiac assessments should be considered for patients exposed to cumulative doxorubicin doses greater than 300 mg/m2 when combined with bevacizumab. 
Ti rezultati kažejo, da je treba bolnike, ki prejemajo kumulativne odmerke doksorubicina, večje od 300 mg/m2, v kombinaciji z bevacizumabom, skrbno klinično opazovati in ustrezno oceniti njihovo srčno funkcijo.
Enrolment in Arm 3 was discontinued, as pre-specified, once safety of bevacizumab with the IFL regimen was established and considered acceptable. 
Ko so dokazali varnost bevacizumaba skupaj s shemo IFL in jo ocenili kot sprejemljivo, so vključevanje v skupino 3 prekinili, kot so predhodno predvideli.
In locally recurrent and metastatic breast cancer trials, Grade 3-5 wound healing complications were observed in up to 1.1% of patients receiving bevacizumab compared with up to 0.9% of patients in the control arms (NCI-CTCAE v.3). 
V preskušanjih pri bolnikih z lokalno ponavljajočim se in metastatskim rakom dojk so zaplete pri celjenju ran stopnje 3-5 opazili pri največ 1,1 % bolnikov, ki so prejemali bevacizumab, v primerjavi z največ 0,9 % bolnikov v kontrolnih skupinah (NCI-CTCAE v.3).
Exfoliative dermatitis, Dry skin, Skin discoloration 
, eksfoliativni dermatitis, suha koža, obarvanje kože sindrom palmarnoplantarne eritrodisestezije
In some clinical trials anaphylactic and anaphylactoid-type reactions were reported more frequently in patients receiving bevacizumab in combination with chemotherapy than with chemotherapy alone. 
V nekaterih kliničnih preskušanjih so o anafilaktičnih reakcijah in reakcijah anafilaktoidne vrste pogosteje poročali pri bolnikih, ki so prejemali bevacizumab v kombinaciji s kemoterapijo, kot pri tistih, ki so prejemali samo kemoterapijo.
Placebo + IFNa 
placebo + IFN
(11.9 vs.14.3 months; p = 0.4825) 
(11,9 meseca v primerjavi s 14,3 meseca; p = 0,4825)
• E3200: Bevacizumab 10 mg/kg of body weight every 2 weeks in combination with leucovorin and 5-fluorouracil bolus, followed by 5-fluorouracil infusion, with intravenous oxaliplatin (FOLFOX-4) in bevacizumab-naïve patients. 
E3200: bevacizumab 10 mg/kg telesne mase vsaka 2 tedna v kombinaciji z levkovorinom in bolusom 5-fluorouracila, čemur je sledila infuzija 5-fluorouracila z intravensko danim oksaliplatinom (shema FOLFOX-4), pri bolnikih, ki se še niso zdravili z bevacizumabom.
(14.9 vs. 11.9 months; p = 0.1061) 
(14,9 meseca v primerjavi z 11,9 meseca; p = 0,1061)
Cisplatin/Gemcitabine + bevacizumab 7.5 mg/kg q 3 weeks 
Cisplatin in gemcitabin + bevacizumab 7,5 mg/kg vsake 3 tedne
(17.5 vs.15.0 months; p = 0.0584) 
(17,5 meseca v primerjavi s 15,0 meseca; p = 0,0584)
The difference in ORR per independent central review was 18% (CI: 0.6%, 35.3%) between the two treatment arms in the few patients who had evaluable tumor at baseline and had a confirmed response prior to receiving any local therapy: 27/75 patients (36.0%, 95% CI: 25.2%, 47.9%) in the Chemo arm and 34/63 patients (54.0%, 95% CI: 40.9%, 66.6%) in the Bv +Chemo arm. 
(IZ: 0,6 %; 35,3 %), in sicer pri maloštevilnih bolnikih, ki so imeli ob izhodišču tumor, ki ga je bilo mogoče oceniti, in potrjen odziv pred prejemom kakršnegakoli lokalnega zdravljenja: 27/75 bolnikov (36,0 %; 95 % IZ: 25,2 %; 47,9 %) v skupini, ki je prejemala kemoterapijo, in 34/63 bolnikov (54,0 %; 95 % IZ: 40,9 %; 66,6 %) v skupini, ki je prejemala bevacizumab + kemoterapijo.
Each ml of concentrate contains 25 mg of bevacizumab. 
En ml koncentrata vsebuje 25 mg bevacizumaba.
Zirabev may impair female fertility. 
Zdravilo Zirabev lahko zmanjša plodnost ženske.
55% bevacizumab/IFN) received a variety of non-specified post-trial anti-cancer therapies, including antineoplastic agents, which may have impacted the analysis of overall survival. 
Velik delež bolnikov (približno 63 % IFN in placebo; 55 % bevacizumab in IFN) je po zaključku preskušanja prejemal različna neopredeljena zdravila za zdravljenje novotvorb, vključno z antineoplastičnimi zdravili, kar je lahko vplivalo na analizo celokupnega preživetja.
Detailed information on this medicinal product is available on the website of the European Medicines Agency (EMA): http://www.ema.europa.eu 
Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila http://www.ema.europa.eu/.
CHF Grade 3 or higher reactions were somewhat more frequent among patients receiving bevacizumab in combination with chemotherapy than in patients receiving chemotherapy alone. 
Neželeni učinki, povezani s KSP 3. ali višje stopnje, so bili nekoliko pogostejši pri bolnikih, ki so prejemali bevacizumab v kombinaciji s kemoterapijo, v primerjavi s tistimi, ki so prejemali samo kemoterapijo.
The recommended dose of Zirabev, administered as an intravenous infusion, is either 5 mg/kg or 10 mg/kg of body weight given once every 2 weeks or 7.5 mg/kg or 15 mg/kg of body weight given once every 3 weeks. 
Priporočeni odmerek zdravila Zirabev, ki ga dajemo v obliki intravenske infuzije, je 5 mg/kg ali 10 mg/kg telesne mase v enkratnem odmerku vsaka 2 tedna ali 7,5 mg/kg ali 15 mg/kg telesne mase v enkratnem odmerku vsake 3 tedne.
There was a small difference, of borderline significance, between the time to progression of disease in the 3 mg/kg group and that in the placebo group (hazard ratio, 1.26; p=0.053). 
Med skupino, ki je prejemala bevacizumab v odmerku 3 mg/kg, in skupino, ki je prejemala placebo, je obstajala majhna, mejna statistično pomembna razlika v času do napredovanja bolezni (razmerje ogroženosti 1,26; p = 0,053).
Anorexia, Hypomagnesaemia, Hyponatraemia 
Presnovne in prehranske motnje anoreksija, hipomagneziemija, hiponatriemija dehidracija
• inflammation of the moist lining of mouth and gut, lungs and air passages, reproductive, 
• vnetje vlažne sluznice ust in črevesja, pljuč in dihalnih poti, spolovil in sečil,
Necrotising fasciitis, including fatal cases, has rarely been reported in patients treated with bevacizumab. 
Pri bolnikih, ki so se zdravili z bevacizumabom, so redko poročali o nekrotizirajočem fasciitisu, vključno s smrtnimi primeri.
Do not use Zirabev if you notice any particulate matter or discolouration prior to administration. 
Zdravila Zirabev ne uporabite, če pred dajanjem opazite prisotnost kakršnihkoli trdnih delcev ali obarvanje.
Table 10 Trial E2100 efficacy results Progression-free survival 
Preglednica 10 Rezultati učinkovitosti v preskušanju E2100
From a clinical trial in patients with persistent, recurrent, or metastatic cervical cancer (study GOG-0240), GI perforations (all grade) were reported in 3.2% of patients, all of whom had a history of prior pelvic radiation. 
V kliničnem preskušanju pri bolnicah z dolgotrajnim, ponavljajočim se ali metastatskim rakom materničnega vratu (študija GOG-0240) so poročali o perforacijah prebavil (vseh stopenj) pri 3,2 % bolnic; vse te bolnice so imele v anamnezi obsevanje medeničnega predela.